secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001437749-25-026931
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros Q2 net loss narrows to $25.4M; narsoplimab PDUFA extended to Dec 2025; debt reduced by $80M
--------------------------------------------------------------------------------

- Net loss of $25.4M ($0.43/sh) vs $56.0M ($0.97/sh) a year ago; cash, short-term investments $28.7M at June 30.
- Post-quarter: raised $20.6M net from Polar Asset Management (5.37M shares at $4.10, 14% premium) plus $2.1M from ATM.
- Narsoplimab BLA PDUFA date extended to Dec 26, 2025; FDA expects labeling talks by Oct. EMA MAA validated, opinion mid-2026.
- Exchanged $70.8M of 2026 Notes for 2029 Notes; remaining 2026 Notes reduced to $17.1M; avoided $20M prepayment on term debt.
- In talks for potential asset deal with multi-billion total value; upfront cash would repay $67.1M term loan and $17.1M notes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000143774925026931/0001437749-25-026931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000143774925026931/omer20250521_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-026931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer